- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Canopy Rivers Releases Quarterly Results, Earns Rosy Review
Marijuana investment company Canopy Rivers earned an “outperformer” rating from CIBC Capital Markets after the release of its latest quarterly earnings report.
Following the release of its fiscal Q1 2020 earnings report on Tuesday (August 27), Canopy Rivers (TSXV:RIV,OTC Pink:CNPOF) earned a glowing review from CIBC Capital Markets.
John Zamparo, equity research analyst with CIBC Capital Markets, reaffirmed that the Canadian company remains his top pick in the sector and assigned a 12 to 18 month price target of C$7.
The cannabis company, an investment division launched by Canopy Growth (NYSE:CGC,TSX:WEED), reported a net loss of C$2.9 million for its most recent quarter.
The analyst said he has rated the stock an “outperformer” because of the company’s approach when it comes to capital allocation, its supply contracts and its valuation, which he said is at an all-time low.
Zamparo noted that, despite the third straight monthly double-digit increase in sales for the cannabis space, there’s been a drop in the performance for some of the players. To explain why this is, the analyst said, “(The industry has) rarely traded on fundamentals.”
Canopy Rivers informed investors it expects to see continuing losses due to the development of its investments across the global cannabis market.
“As these equity method investees continue to ramp-up operationally over the coming quarters, management expects to continue to recognize its share of net losses during the remainder of the fiscal year,” the company said in a statement.
Narbe Alexandrian, president and CEO of the firm, also highlighted the development of its investee PharmHouse, which signed a supply agreement with Canopy Growth in May.
Despite its losses, Canopy Rivers CFO Eddie Lucarelli said the company holds strong potential to maintain its position moving forward. In a statement, he said:
“While some of our financial results are linked to the public markets and therefore subject to volatility, we believe that several factors — including significant business catalysts within our portfolio, operational improvements that translate into increased production at our royalty investees, and an operating expense base that is low by cannabis sector standards — position us well to create value for our shareholders in the long term.”
Shares of Canopy Rivers fell after its results release. The decline of just over 5 percent resulted in the company opening Wednesday’s trading session at a price per share of C$2.22. As of 3:48 p.m. EDT on Wednesday, shares of Canopy Rivers were trading at C$2.20, indicating a drop of almost 1 percent.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.